CorMedix Inc.
No SEC Form 4 filings for $CRMD in the last 30 days.
See all $CRMD insider activity →CorMedix (NASDAQ:CRMD) reported Q2 revenue rising to $39.7M from $39.7M a year earlier, with 2026 including $66.1M DefenCath sales and $35.8M from the Melinta portfolio. Net income was $26.0M ($0.33 basic). It reaffirmed 2026 revenue guidance of $325M-$345M and raised adjusted EBITDA to $125M-$140M. REZZAYO supplemental NDA is planned for Q3 2026, with FDA action expected H1 2027.
CorMedix Inc. shares rose 17% after Q2 2026 results. The company reported revenue of $101.9M, nearly tripling from $39.7M a year earlier, and raised full-year adjusted EBITDA guidance to $125M to $140M. DefenCath revenue was $66.1M. CorMedix plans a Q3 2026 FDA filing for Rezzayo sNDA.
CorMedix Therapeutics (Nasdaq: CRMD) reported Q2 2026 consolidated revenue of $101.9M, including $66.1M DefenCath sales and $35.8M from the Melinta portfolio. Net income was $26.0M and adjusted EBITDA $58.7M. The company maintained FY2026 revenue guidance at $325M-$345M and raised adjusted EBITDA to $125M-$140M, with a REZZAYO sNDA FDA submission expected in Q3 2026.
Over the past 7 days, alphai's AI scored 4 news stories mentioning CRMD (CorMedix Inc.). Coverage has skewed bullish: 4 bullish, 0 neutral, and 0 bearish.
Recent CRMD coverage spans financial news, earnings and corporate actions.
Guidance and pipeline milestones (REZZAYO supplemental NDA in Q3, DefenCath TPN protocol amendment) can re-rate near-term risk and launch optionality.
Raised profitability outlook plus strong Q2 revenue and cash generation likely supports near-term momentum, but FDA timing for Rezzayo remains a key overhang.
Guidance raise plus an anticipated REZZAYO sNDA submission window and a new DefenCath supply agreement are near-term catalysts for CRMD.
Guidance raise plus FDA submission timing for REZZAYO sNDA and a new DefenCath supply agreement are near-term catalysts for CRMD’s revenue and margin outlook.
The filing confirms outcomes of governance proposals (some approved, others not), which can affect corporate governance and future proxy contests but provides no operational or financial change.
alphai scores every news story that mentions CRMD with an AI model for sentiment and relevance, and aggregates insider trades from CorMedix Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
CorMedix (NASDAQ:CRMD) reported Q2 revenue rising to $39.7M from $39.7M a year earlier, with 2026 including $66.1M DefenCath sales and $35.8M from the Melinta portfolio. Net income was $26.0M ($0.33 basic). It reaffirmed 2026 revenue guidance of $325M-$345M and raised adjusted EBITDA to $125M-$140M. REZZAYO supplemental NDA is planned for Q3 2026, with FDA action expected H1 2027.
6 min readCorMedix Inc. shares rose 17% after Q2 2026 results. The company reported revenue of $101.9M, nearly tripling from $39.7M a year earlier, and raised full-year adjusted EBITDA guidance to $125M to $140M. DefenCath revenue was $66.1M. CorMedix plans a Q3 2026 FDA filing for Rezzayo sNDA.
6 min readCorMedix Therapeutics (Nasdaq: CRMD) reported Q2 2026 consolidated revenue of $101.9M, including $66.1M DefenCath sales and $35.8M from the Melinta portfolio. Net income was $26.0M and adjusted EBITDA $58.7M. The company maintained FY2026 revenue guidance at $325M-$345M and raised adjusted EBITDA to $125M-$140M, with a REZZAYO sNDA FDA submission expected in Q3 2026.
6 min readCorMedix Inc. (CRMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 crmd_q22026earningspr.htm EX-99.1 Document Exhibit 99.1 CORMEDIX THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ‒ Q2 2026 Consolidated Revenue of $101.9 million ‒ ‒ Q2 2026 Net Income of $26.0 million ; Adjusted EBITDA of $58.7 m
7 min readCorMedix Inc. (CRMD) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. crmd-20260623 FALSE 0001410098 0001410098 2026-06-23 2026-06-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
3 min readCorMedix (CRMD) shares surged over 18% after the company reported strong first-quarter results, with revenue reaching $127.4 million, significantly exceeding Wall Street's expectations. The impressive growth was largely driven by DefenCath sales, prompting CorMedix to raise its full-year 2026 revenue and adjusted EBITDA guidance. Retail sentiment on Stocktwits also shifted to bullish following the positive news.
3 min readThis article analyzes the financial performance of CorMedix Inc (CRMD), focusing on its revenue breakdown, profitability margins, and competitive positioning. CRMD boasts a gross margin of 83.43%, an operating margin of 45.97%, and a net margin of 10.90%, alongside a Return on Equity (ROE) of 66.56%. The article also compares CRMD's market capitalization of $536.75M and its gross margin against competitors CTNM and CMPS, for which gross margin data is N/A.
4 min readInsmed's stock has surged 78% in six months, largely due to the FDA approval of Brinsupri, its second marketed product, which generated $28.1 million in its first quarter. The company also benefits from steady sales of Arikayce and continues to advance its pipeline despite a recent setback in a phase IIb study. Several other biotech stocks like ANI Pharmaceuticals, CorMedix, and Castle Biosciences also show strong performance.
4 min readJanet Dillione, Director at Cormedix ( NASDAQ:CRMD ) , reported an insider sell on November 19, according to a new SEC filing. What Happened: Dillione's recent Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday unveiled the sale of 30,000 shares of Cormedix.
3 min readCorMedix Inc. ( NASDAQ:CRMD ) reported third-quarter earnings of $1.26 per share on Wednesday, beating the consensus of 63 cents. Sales reached $104.27 million, a jump from $11.5 million a year ago, beating the consensus of $86.02 million.
2 min read
